GIP and GLP-1 dual agonists, such as Mounjaro, enable insulin secretion through activation of β-cell GIP receptors and appear to greatly enhance the satiety and weight loss encountered with GLP-1R activation alone, aiding obesity [129,130]. Here, GIP is linked to obesity disorder.